BPC-157 vs PT-141
A comprehensive, data-driven comparison of BPC-157 (Body Protection Compound-157) and PT-141 (Bremelanotide). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | BPC-157 Body Protection Compound-157, PL 14736 | PT-141 Bremelanotide, Vyleesi |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | FDA Approved |
| Category | Recovery & Healing | Sexual Health |
| Primary Use | Tissue healing and injury recovery | Hypoactive sexual desire disorder (HSDD) in women |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $50 - $120/mo | $800 - $1,200/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 250-500mcg daily | 1.75mg as needed, at least 45 min before activity |
| Frequency | Daily | As needed |
| Mechanism | Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth factors, and accelerates tissue repair | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Low | High |
| Clinical Trial Phase | N/A | Approved |
Key Differences
- 1PT-141 is FDA-approved, while BPC-157 is currently category 2 (pending reclassification).
- 2BPC-157 is generally more affordable ($50 - $120/mo) compared to PT-141 ($800 - $1,200/mo).
- 3BPC-157 is dosed daily, while PT-141 is as needed.
- 4PT-141 has high-quality evidence, while BPC-157 has low-quality evidence.
- 5They belong to different categories: BPC-157 (Recovery & Healing) vs PT-141 (Sexual Health).
Which Is Better For...
PT-141
Those seeking an FDA-approved treatment with established safety data
BPC-157
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
BPC-157
Fewer commonly reported side effects
PT-141
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| BPC-157 | $50 - $120/mo | Category 2 (pending reclassification) | Various research labs |
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
BPC-157 works via Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth. PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. They differ in FDA approval status, efficacy data, and cost.
BPC-157 typically costs $50 - $120/mo, while PT-141 costs $800 - $1,200/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
BPC-157 is not FDA-approved (Category 2 (pending reclassification)). PT-141 is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of BPC-157 include Injection site discomfort, Mild headache, Dizziness. Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
BPC-157 is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. Although not FDA-approved, it has gained significant attention in research a...
View Full BPC-157 GuidePT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between BPC-157 and PT-141 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.